Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals a weak financial performance with a 5% revenue decline and a 10% drop in EPS, despite slight improvements in gross margin and operating cash flow. The absence of strategic initiatives and outlook discussions further adds uncertainty. The market may react negatively, especially with higher operating expenses and interest costs impacting net income.
Revenue Revenue for Q1 2026 was $1.3 billion, representing a 5% decrease year-over-year. The decline was attributed to weaker demand in key markets and unfavorable currency exchange rates.
Gross Margin Gross margin was 78.2%, a slight improvement from 77.8% in Q1 2025. This increase was due to cost optimization initiatives and a favorable product mix.
Net Income Net income for the quarter was $85 million, down 12% year-over-year. The decrease was primarily due to higher operating expenses and increased interest costs.
Earnings Per Share (EPS) Earnings per share were $0.75, a 10% decline compared to Q1 2025. This was driven by the same factors affecting net income.
Operating Cash Flow Operating cash flow was $120 million, a 15% increase year-over-year. The improvement was attributed to better working capital management.
The selected topic was not discussed during the call.
The selected topic was not discussed during the call.
The selected topic was not discussed during the call.
The selected topic was not discussed during the call.
The earnings call reveals a weak financial performance with a 5% revenue decline and a 10% drop in EPS, despite slight improvements in gross margin and operating cash flow. The absence of strategic initiatives and outlook discussions further adds uncertainty. The market may react negatively, especially with higher operating expenses and interest costs impacting net income.
The earnings report shows strong performance in key areas like Adjusted EBITDA, operating cash flow, and debt reduction. Despite some challenges like FX headwinds and regional sales declines in China, the company has demonstrated financial discipline and strategic growth initiatives. The Q&A highlights optimism in future growth, particularly in India, and strategic focus on personalized nutrition. However, lack of detailed guidance for China and minimal contribution from Pro2col slightly temper the outlook. Overall, the positive financial metrics and strategic initiatives are expected to boost the stock price in the short term.
The company has shown positive financial performance with debt reduction, regional sales growth, and promising product launches. The Q&A session highlighted strong engagement and feedback for new products, with no anticipated increase in SG&A costs. The raised guidance and strategic focus on subscription revenue and new product lines further support a positive outlook. Despite some lack of detail on profitability differences, overall market sentiment appears optimistic, suggesting a positive stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.